12:00 AM
 | 
Mar 15, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Integrilin eptifibatide Injection: Marketed to treat unstable angina and non-Q-wave myocardial infarction and as an adjunct to coronary angioplasty

Additional analysis of CORR's and partner Schering-Plough Corp.'s Phase III PURSUIT study showed that Integrilin reduced myocardial infarction over 30 days compared to placebo in acute coronary syndrome patients. Integrilin also reduced the extent of injury...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >